



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on September 3, 2003.

Doran R. Pace, Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Examining Group 1635
Patent Application
Docket No. USF-T176X
Serial No. 09/744,875

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Mary M. Schmidt
Art Unit : 1635
Applicants : Kenneth S. Zuckerman, Richard Y. Liu
Serial No. : 09/744,875
Filed : January 29, 2001
Conf. No. : 8728
For : Method for the Inhibition of Function of STAT Transcription Factors

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Doran R. Pace
Patent Attorney
Registration No. 38,261
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRP/tl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/744,875
Filing Date	January 29, 2001
First Named Inventor	Kenneth S. Zuckerman
Group Art Unit	1635
Examiner Name	Mary M. Schmidt
Attorney Docket Number	USF-T176X

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	DUSANTER-FOURT <i>et al.</i> "Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin- erythropoietin receptor chimera expressed in lymphoid cells," <i>The EMBO Journal</i> , 1994, Vol. 13, No. 11, pp. 2583-2591.	
	R2	GEWIRTZ <i>et al.</i> "Nucleic Acid Therapeutics: State of the Art and Future Prospects," <i>Blood</i> , 1998, Vol. 92, No. 3, pp. 712-736.	
	R3	GORODETSKY <i>et al.</i> "Isolation and characterization of the <i>Bos Taurus</i> β -casein gene," <i>Gene</i> , 1988, Vol. 66, pp. 87-96.	
	R4	GREENBERG <i>et al.</i> "Characterization of a New Megakaryocytic Cell Line: The Dami Cell," <i>Blood</i> , 1988, Vol. 72, No. 6, pp. 1968-1977.	
	R5	HONG <i>et al.</i> "Inhibition of Protein Kinase C Suppresses Megakaryocytic Differentiation and Stimulates Erythroid Differentiation in HEL Cells," <i>Blood</i> , 1996, Vol. 87, No. 1, pp. 123-131.	
	R6	MARTIN "HEL Cells: A New Human Erythroleukemia Cell Line with Spontaneous and Induced Globin Expression," <i>Science</i> , 1982, Vol. 216, pp. 1233-1235.	
	R7	OGURA <i>et al.</i> "Establishment of a Novel Human Megakaryoblastic Leukemia Cell Line, MEG-01, With Positive Philadelphia Chromosome," <i>Blood</i> , 1985, Vol. 66, No. 6, pp. 1384-1392.	
	R8	IYER <i>et al.</i> "The Automated Synthesis of Sulfur-Containing Oligodeoxyribonucleotides Using 3H-1,2-Benzodithiol-3-one 1,1-Dioxide as a Sulfur-Transfer Reagent," <i>J. Org. Chem.</i> , 1990, Vol. 55, pp. 4693-4699.	
	R9	WOOLF <i>et al.</i> "The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in <i>Xenopus</i> oocytes and embryos," <i>Nucleic Acids Research</i> , 1990, Vol. 18, No. 7, pp. 1763-1769.	
	R10	YU <i>et al.</i> "Attenuation of Serum Inducibility of Immediate Early Genes by Oncoproteins in Tyrosine Kinase Signaling Pathways," <i>Molecular and Cellular Biology</i> , 1993, Vol. 13, No. 4, pp. 2011-2019.	
	R11	Appleton & Lange, Critical Care Diagnosis & Treatment, Edited by Frederic S. Bongard and Darryl Y. Sue, Paramount Publishing Business and Professional Group.	
	R12	PCR Protocols: A Guide to Methods and Applications, Edited by Michael A. Innis <i>et al.</i> , Academic Press, Inc., 1990.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.